A US FDA advisory committee's strong recommendation against use of opioid-containing antitussives for pediatric cough suggests sponsors of such products are likely to face further labeling restrictions but also could be relieved of some postmarketing study requirements.
In a series of votes Sept
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?